Liu Jing, Song Lin, Zou Wei, Zhuge Dong, Cui Zhanfeng
Centre for Regenerative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
Sheng Wu Gong Cheng Xue Bao. 2010 Dec;26(12):1629-35.
The multipotent differentiation and immunosuppression capability of mesenchymal stem cells (MSCs) make it attractive source for stem cell therapy to treat serious diseases, including neural system diseases and immune disorders. For large scale clinical applications, MSCs have to be expanded to produce sufficient quantity for multiple treatments. While conventional passaging is not appropriate for such a task, bioreactor can be used to expand MSCs more efficiently. Yet the efficacy and biosafety of expanded MSCs must be properly assessed before the expanded MSCs can be implanted. This review presented state-of-the-art in expanding MSCs focusing on the progress on the assessment of the efficacy and biosafety of in vitro expanded MSCs. Current obstacles were discussed and future research directions were outlined.
间充质干细胞（MSCs）的多能分化和免疫抑制能力使其成为用于治疗包括神经系统疾病和免疫紊乱在内的严重疾病的干细胞疗法的有吸引力的来源。对于大规模临床应用，必须扩增MSCs以产生足够数量用于多次治疗。虽然传统传代不适用于此任务，但生物反应器可用于更有效地扩增MSCs。然而，在植入扩增的MSCs之前，必须对其功效和生物安全性进行适当评估。本综述介绍了扩增MSCs的最新技术，重点是体外扩增MSCs的功效和生物安全性评估的进展。讨论了当前的障碍并概述了未来的研究方向。
